Dacarbazine_for: profile and news

Genasense(R) New Drug Application Accepted for Review by FDA Mar 1, 2006
Genta has also filed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - Yahoo! News (press release)

Randomized Trial Shows Ganite(R) Effective When Compared with a ... Mar 2, 2006
Genta has also submitted a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - PR Newswire (press release),

Genasense(R) Marketing Authorization Application in Melanoma ... Feb 1, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, particularly for patients for ... - PR Newswire (press release),

Highlights of rising and falling US stocks Feb 2, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, the Berkeley Heights, NJ-based ... - Investor's Business Daily (subscription)

Genta Incorporated to Present in Roundtable and Corporate Sessions ... Feb 7, 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - PR Newswire (press release),

International Approvals: Tasmar, Amplimexon, IV Remodulin Jan 17, 2006
1/2 clinical studies in combination with gemcitabine for the first-line treatment of advanced pancreatic adenocarcinoma; with dacarbazine for the treatment of ... - Medscape (subscription)

FDA Approvals: Amplimexon, AP23573, TQ-1017 Sep 6, 2005
It is currently in phase 1/2 clinical studies in combination with gemcitabine for the treatment of pancreatic cancer, and with dacarbazine for the treatment of ... - Medscape (subscription)

AmpliMed Begins Patient Enrollment for Phase I/II Trial of ... Jul 13, 2005
AmpliMed today announced that the Company has begun to enroll patients in a new clinical trial that will evaluate its lead candidate, Amplimexon(TM) (imexon inj ... - Genetic Engineering News

AmpliMed Begins Patient Enrollment for Phase I/II Trial of ... Jul 13, 2005
TUCSON, Ariz.--(BUSINESS WIRE)--Jul 13, 2005 - AmpliMed today announced that the Company has begun to enroll patients in a new clinical trial that will ... - PharmaLive.com (press release)